{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:45:29Z","timestamp":1790376329210,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.celrep.2022.111081","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T11:23:12Z","timestamp":1657624992000},"page":"111081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Guiding ATR and PARP inhibitor combinations with chemogenomic screens"],"prefix":"10.1016","volume":"40","author":[{"given":"Michal","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Skeldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Rimkunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan T.F.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roulston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2022.111081_bib1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s43018-021-00266-w","article-title":"The CIP2A\u2013TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer","volume":"2","author":"Adam","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2022.111081_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/bcr2619","article-title":"RAD51C germline mutations in breast and ovarian cancer patients","volume":"12","author":"Akbari","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.celrep.2022.111081_bib3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2022.111081_bib4","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1101\/gad.1839909","article-title":"The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks","volume":"23","author":"Bansbach","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2022.111081_bib5","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1038\/s41467-020-17324-z","article-title":"Sequential role of RAD51 paralog complexes in replication fork remodeling and restart","volume":"11","author":"Berti","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2022.111081_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","article-title":"RAD51 gene family structure and function","volume":"54","author":"Bonilla","year":"2020","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.celrep.2022.111081_bib7","doi-asserted-by":"crossref","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as Cancer Therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.celrep.2022.111081_bib8","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2022.111081_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2022.111081_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.111081_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome Atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2022.111081_bib12","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.molcel.2021.07.015","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2022.111081_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-Part Trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2022.111081_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fonc.2016.00186","article-title":"Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition","volume":"6","author":"Deeg","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.celrep.2022.111081_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","article-title":"scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.celrep.2022.111081_bib16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.celrep.2020.01.020","article-title":"A P53-independent DNA damage response suppresses oncogenic proliferation and genome instability","volume":"30","author":"Fagan-Solis","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2022.111081_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2022.111081_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.111081_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.1257216","article-title":"Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.celrep.2022.111081_bib20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2022.111081_bib21","doi-asserted-by":"crossref","first-page":"101147","DOI":"10.1016\/j.tranon.2021.101147","article-title":"Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity","volume":"14","author":"Garbarino","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.celrep.2022.111081_bib22","article-title":"Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy (preprint)","author":"Garc\u00eda","year":"2020","journal-title":"Cancer Biol."},{"key":"10.1016\/j.celrep.2022.111081_bib23","doi-asserted-by":"crossref","first-page":"e1008355","DOI":"10.1371\/journal.pgen.1008355","article-title":"Differential requirements for the RAD51 paralogs in genome repair and maintenance in human cells","volume":"15","author":"Garcin","year":"2019","journal-title":"PLoS Genet."},{"key":"10.1016\/j.celrep.2022.111081_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/1471-2407-13-484","article-title":"Germline mutation in the RAD51B gene confers predisposition to breast cancer","volume":"13","author":"Golmard","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.celrep.2022.111081_bib25","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1534\/g3.117.041277","article-title":"Evaluation and design of genome-wide CRISPR\/SpCas9 knockout screens","volume":"7","author":"Hart","year":"2017","journal-title":"G3 (Bethesda)"},{"key":"10.1016\/j.celrep.2022.111081_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.seminoncol.2016.02.007","article-title":"Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade","volume":"43","author":"Herman","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.celrep.2022.111081_bib27","article-title":"Inference of CRISPR Edits from sanger trace data (preprint)","author":"Hsiau","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2022.111081_bib28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.111081_bib29","doi-asserted-by":"crossref","first-page":"190156","DOI":"10.1098\/rsob.190156","article-title":"A consensus set of genetic vulnerabilities to ATR inhibition","volume":"9","author":"Hustedt","year":"2019","journal-title":"Open Biol."},{"key":"10.1016\/j.celrep.2022.111081_bib30","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2022.111081_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.111081_bib32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2022.111081_bib33","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1021\/jm5018237","article-title":"Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination","volume":"58","author":"Jones","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.celrep.2022.111081_bib34","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2022.111081_bib35","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2022.111081_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2022.111081_bib37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2022.111081_bib38","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2022.111081_bib39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1101\/gad.333963.119","article-title":"Telomere length heterogeneity in ALT cells is maintained by PML-dependent localization of the BTR complex to telomeres","volume":"34","author":"Loe","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2022.111081_bib40","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2022.111081_bib41","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1038\/s41467-019-13097-2","article-title":"The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)","volume":"10","author":"Lu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2022.111081_bib42","doi-asserted-by":"crossref","first-page":"D394","DOI":"10.1093\/nar\/gkaa1106","article-title":"PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API","volume":"49","author":"Mi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2022.111081_bib43","doi-asserted-by":"crossref","first-page":"eabl9794","DOI":"10.1126\/sciadv.abl9794","article-title":"RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer","volume":"8","author":"Miao","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2022.111081_bib44","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2022.111081_bib45","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2022.111081_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2022.111081_bib47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2022.111081_bib48","doi-asserted-by":"crossref","first-page":"107669","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2022.111081_bib49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","article-title":"A genetic map of the response to DNA damage in human cells","volume":"182","author":"Olivieri","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2022.111081_bib50","doi-asserted-by":"crossref","first-page":"100321","DOI":"10.1016\/j.xpro.2021.100321","article-title":"Genome-scale chemogenomic CRISPR screens in human cells using the TKOv3 library","volume":"2","author":"Olivieri","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.celrep.2022.111081_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.celrep.2022.111081_bib52","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/hmg\/ddu485","article-title":"Reduction of hRNase H2 activity in Aicardi-Gouti\u00e8res syndrome cells leads to replication stress and genome instability","volume":"24","author":"Pizzi","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.celrep.2022.111081_bib53","doi-asserted-by":"crossref","first-page":"14864","DOI":"10.1073\/pnas.1510750112","article-title":"SMARCAL1 maintains telomere integrity during DNA replication","volume":"112","author":"Poole","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.celrep.2022.111081_bib54","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2022.111081_bib55","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1074\/jbc.M110.177394","article-title":"The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease","volume":"286","author":"Reijns","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2022.111081_bib56","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1042\/BST20140079","article-title":"Ribonuclease H2 in health and disease","volume":"42","author":"Reijns","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.celrep.2022.111081_bib57","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cell.2012.04.011","article-title":"Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development","volume":"149","author":"Reijns","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2022.111081_bib58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.gde.2021.06.010","article-title":"RAD51 paralog function in replicative DNA damage and tolerance","volume":"71","author":"Rein","year":"2021","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.celrep.2022.111081_bib59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic germline BRCA-mutated breast cancer","volume":"377","author":"Robson","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2022.111081_bib60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2022.111081_bib61","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2022.111081_bib62","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.celrep.2019.09.008","article-title":"ATR signaling uncouples the role of RAD51 paralogs in homologous recombination and replication stress response","volume":"29","author":"Saxena","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2022.111081_bib63","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.celrep.2022.111081_bib64","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1158\/2159-8290.CD-20-1503","article-title":"Synthetic lethality in cancer therapeutics: the next generation","volume":"11","author":"Setton","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2022.111081_bib65","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2022.111081_bib66","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1038\/s41467-019-10179-z","article-title":"FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops","volume":"10","author":"Silva","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2022.111081_bib67","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1158\/0008-5472.CAN-12-3976","article-title":"ATR-dependent phosphorylation of FANCM at serine 1045 is essential for FANCM functions","volume":"73","author":"Singh","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2022.111081_bib68","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1093\/nar\/gkaa279","article-title":"Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart","volume":"48","author":"Somyajit","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2022.111081_bib69","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","article-title":"Targeting the DNA repair pathway in Ewing sarcoma","volume":"9","author":"Stewart","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2022.111081_bib70","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2022.111081_bib71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-biochem-062917-012415","article-title":"The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair","volume":"87","author":"Syed","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.celrep.2022.111081_bib72","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2022.111081_bib73","doi-asserted-by":"crossref","first-page":"16910","DOI":"10.1073\/pnas.1009843107","article-title":"Allele-specific copy number analysis of tumors","volume":"107","author":"Van Loo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.celrep.2022.111081_bib74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1101\/gad.319723.118","article-title":"RAD52 and SLX4 act nonepistatically to ensure telomere stability during alternative telomere lengthening","volume":"33","author":"Verma","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2022.111081_bib75","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","article-title":"Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2022.111081_bib76","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.celrep.2022.111081_bib77","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(16)32607-7","article-title":"Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers","volume":"69","author":"Yap","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.celrep.2022.111081_bib78","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.celrep.2022.111081_bib79","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.celrep.2018.12.102","article-title":"Alternative lengthening of telomeres through two distinct break-induced replication pathways","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2022.111081_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13578-020-00391-6","article-title":"Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.celrep.2022.111081_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124722008798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124722008798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:45:25Z","timestamp":1761911125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124722008798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2211124722008798"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2022.111081","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.13.472393","asserted-by":"object"}]},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guiding ATR and PARP inhibitor combinations with chemogenomic screens","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2022.111081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"111081"}}